INO(Inovio Pharmaceuticals, Inc.) · 财务报表

INO(Inovio Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$1.77M$10.26M$832.01K$217.76K$65.34K
毛利润—————
营业利润−$301.22M−$267.57M−$143.94M−$112.40M−$86.82M
净利润−$303.66M−$279.82M−$135.12M−$107.25M−$84.95M
经营现金流−$215.71M−$216.22M−$124.37M−$104.08M−$88.63M
自由现金流−$216.94M−$217.18M−$124.69M−$104.56M−$88.92M
摊薄每股收益$-17.45$-14.07$-6.09$-3.95$-1.81

Inovio Pharmaceuticals, Inc. INO